PubRank

Yiling Lu

Author PubWeight™ 141.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005 11.46
2 Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006 7.73
3 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
4 High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011 4.78
5 AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009 4.71
6 A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007 4.35
7 Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005 4.18
8 Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006 4.13
9 Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009 3.36
10 A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 2010 3.25
11 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
12 The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008 2.63
13 Modeling precision treatment of breast cancer. Genome Biol 2013 2.42
14 Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002 2.37
15 A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008 2.30
16 Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013 2.29
17 Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007 2.28
18 Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012 2.27
19 Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 2010 2.10
20 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002 1.91
21 Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2003 1.91
22 Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell 2011 1.89
23 Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011 1.81
24 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003 1.74
25 TCPA: a resource for cancer functional proteomics data. Nat Methods 2013 1.64
26 Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010 1.62
27 Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008 1.61
28 Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010 1.59
29 Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009 1.48
30 Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010 1.38
31 A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 2006 1.36
32 Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009 1.30
33 Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010 1.27
34 Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006 1.25
35 Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 2012 1.23
36 Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002 1.22
37 Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Sci Signal 2012 1.19
38 Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 2005 1.18
39 Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 2012 1.17
40 Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics 2012 1.17
41 Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 2004 1.17
42 Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 2013 1.17
43 EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 2011 1.17
44 PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 2010 1.15
45 Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 2002 1.14
46 Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 2006 1.11
47 Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 2008 1.09
48 Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2004 1.08
49 Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 2003 1.07
50 LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 2012 1.07
51 Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem 2009 1.04
52 A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 2014 1.03
53 Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 2005 1.03
54 Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003 1.01
55 Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014 1.01
56 Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2012 1.00
57 BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal 2013 0.97
58 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 2011 0.97
59 Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 2013 0.96
60 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009 0.95
61 Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 2010 0.94
62 Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016 0.93
63 Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol 2008 0.92
64 Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 2012 0.91
65 Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Rep 2012 0.90
66 Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 2014 0.89
67 A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med 2013 0.88
68 Molecular therapeutics: promise and challenges. Semin Oncol 2004 0.86
69 Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 2008 0.85
70 Bayesian models based on test statistics for multiple hypothesis testing problems. Bioinformatics 2008 0.84
71 Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem 2007 0.84
72 Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 2009 0.84
73 Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One 2012 0.83
74 A time-series DDP for functional proteomics profiles. Biometrics 2012 0.80
75 ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 2009 0.80
76 Network inference using steady-state data and Goldbeter-Koshland kinetics. [corrected]. Bioinformatics 2012 0.79
77 Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 2003 0.78
78 Identification and polymorphism discovery of the cathelicidins, Lf-CATHs in ranid amphibian (Limnonectes fragilis). FEBS J 2013 0.77
79 Molecular cloning, sequence analysis and homology modeling of the first caudata amphibian antifreeze-like protein in axolotl (Ambystoma mexicanum). Zoolog Sci 2013 0.76
80 Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 2015 0.76
81 Molecular cloning, sequence analysis and phylogeny of first caudata g-type lysozyme in axolotl (Ambystoma mexicanum). Zoolog Sci 2013 0.75
82 Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 2017 0.75
83 Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers. Pharmazie 2013 0.75
84 [Construction of novel thioredoxin fusion protein expression system and the production of recombinant Lf-CATH2]. Sheng Wu Gong Cheng Xue Bao 2015 0.75